中国医学创新Issue(28)：4-5,2.DOI:10.3969/j.issn.1674-4985.2012.28.002
DC-CIK联合化疗治疗晚期非小细胞肺癌的近期临床疗效
Immediate Clinical Effects of Administering Dendritic Cells and Cytokine Induced Killer Cells Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer
何佳 1李靖 2莫明聪3
作者信息
- 1. 中山大学附属肿瘤医院生物治疗中心 广东 广州 510080
- 2. 广州普天达盛生物科技有限公司
- 3. 广州医学院第一附属医院
- 折叠
摘要
Abstract
Objective:To investigate immediate effects and adverse reaction of administering dendritic cells(DC) and cytokine induced killer cells(CIK) combined with chemotherapy in patients with advanced non-small cell lung cancer(NSCLC).Method:According to random number form,62 cases ofⅢ-Ⅳadvanced NSCLC patients were divided two groups randomly:treatment group and control group. The treatment group received DC-CIK combined with NP chemotherapy.The control group received only NP chemotherapy.The size of the tumor,T lymphocyte subtypes in peripheral blood and adverse reaction of the two group patients were analyzed and controlled.Result:The effect effective rate of tumor change of treatment group was 45.16%, showed no significant difference compare with 32.26%of control group.Stability rate of tumor change of treatment group was 83.87%,significant higher than 61.29%of control group(P<0.05).The levels of T lymphocyte subtypes of treatment group showed no difference after treatment(P>0.05),while the level of CD3+、CD4+and CD4+/CD8+decreased compare with before treatment(P<0.05).There was no difference of adverse reaction between two group. Conclusion:Compared with control group,using DC-CIK combined with chemotherapy have better immediate clinical effects.It can effective control tumor and elevate cellular immune function of patients.关键词
DC-CIK/非小细胞肺癌/NP化疗Key words
DC-CIK/Non-small cell lung cancer/NP chemotherapy引用本文复制引用
何佳,李靖,莫明聪..DC-CIK联合化疗治疗晚期非小细胞肺癌的近期临床疗效[J].中国医学创新,2012,(28):4-5,2.
